Clinical Trials Browser

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Disease Progression

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Rectal Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Neoplasm Metastasis, Sarcoma

Carcinoma, Hepatocellular

Liver Metastasis Colon Cancer

Esophageal Neoplasms

Rectal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

MSI-H Colorectal Cancer

Gastrointestinal Stromal Tumors

Colorectal Neoplasms

Colorectal Neoplasms

Neoplasm Metastasis

Osteosarcoma

Chondroma, Chondrosarcoma, Osteosarcoma

Thyroid Neoplasms

Carcinoma, Adenoid Cystic

Gastrointestinal Stromal Tumors

Carcinoma, Hepatocellular

Colorectal Neoplasms

Ovarian Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Glioblastoma

Colonic Neoplasms

Colorectal Neoplasms

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Rectal Neoplasms

Advanced Colorectal Cancer in the Third-line Treatment and Beyond

Colorectal Neoplasms

Carcinoma, Hepatocellular

Stomach Neoplasms

Liver Metastases

Colonic Neoplasms, Colorectal Neoplasms

Colonic Neoplasms, Neoplasm Metastasis

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Colorectal Neoplasms

Microsatellite Stable Metastatic Colorectal Cancer

Colorectal Neoplasms

Colorectal Neoplasms

Hematologic Neoplasms

Clinical Trials

RELEVANT-HCC

RECOMEND

TAPUR

REGINA

MIRAGE

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

REVIVE

EREMISS

REGO-SARC

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

DREAM

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

PARERE

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

MegaMOST

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

REGOBONE

A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

LEAF-02

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

x-МАР

SED-RO-ICC

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.

SOREGATT

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

a-MANTRA

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

THYMI

CARE

REPROGRAM-01

Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

SLOT

Regorafenib in Metastatic Colorectal Cancer

ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

FINPROVE